← back to search

Sunder Mudaliar

University of San Diego · US
Area of research
Endocrinology, Diabetes and Metabolism · Molecular Biology
Research interest
Research interests include Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer, Diabetes, Cardiovascular Risks, and Lipoproteins, and Diabetes Management and Research.
h-index
57
citations
15,672
works
170
NIH funding
primary concept
email

Recent publications

Weight Gain Was Associated With Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial
Diabetes Care 2025cited by 3position: middledoi
Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)
Circulation 2024cited by 21position: middledoi
Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
2024cited by 17position: contributordoi
Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia
Diabetes Obesity and Metabolism 2023cited by 41position: middledoi
Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes
JAMA Internal Medicine 2023cited by 34position: middledoi
Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia.
2023cited by 28position: contributordoi
Increase in hematocrit with SGLT-2 inhibitors - Hemoconcentration from diuresis or increased erythropoiesis after amelioration of hypoxia?
2023cited by 21position: contributordoi
Sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice
Diabetes Obesity and Metabolism 2022cited by 39position: middledoi
SGLT2 Inhibitor-Induced Low-Grade Ketonemia Ameliorates Retinal Hypoxia in Diabetic Retinopathy-A Novel Hypothesis.
2021cited by 28position: contributordoi
Sodium-Glucose Cotransporter Type 2 (SGLT-2) Inhibitors and Ketogenesis: the Good and the Bad.
2020cited by 27position: contributordoi
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes.
2019cited by 137position: contributordoi
Predictive factors associated with three years of response to HbA1c goals with exenatide QW or insulin glargine: Post-hoc analysis of the DURATION-3 study.
2019cited by 1position: contributordoi
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
Diabetes Obesity and Metabolism 2018cited by 196position: middledoi
Efficacy of Autologous Bone Marrow-Derived Mesenchymal Stem Cell and Mononuclear Cell Transplantation in Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Comparative Study
Stem Cells and Development 2016cited by 120position: middledoi
Altered Myokine Secretion Is an Intrinsic Property of Skeletal Muscle in Type 2 Diabetes
PLoS ONE 2016cited by 64position: middledoi
Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport
Diabetes Care 2015cited by 225position: firstdoi
Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects
Diabetes Care 2014cited by 58position: middledoi
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Gastroenterology 2013cited by 912position: firstdoi
Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion
Diabetes Care 2013cited by 262position: middledoi
Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers
The Journal of Clinical Endocrinology & Metabolism 2013cited by 250position: lastdoi
Prevention of Diabetes With Pioglitazone in ACT NOW
Diabetes 2013cited by 102position: middledoi
Prediction of Diabetes Based on Baseline Metabolic Characteristics in Individuals at High Risk
Diabetes Care 2013cited by 64position: middledoi
The incretin hormones: from scientific discovery to practical therapeutics
Diabetologia 2012cited by 48position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Robert R. Henry · University of Colorado Denver11 papers (2012–2023)Theodore P. Ciaraldi · University of California San Diego6 papers (2013–2023) · 5 papers (2020–2024) · 3 papers (2013–2018)Jeremy Pettus · University of Colorado Denver3 papers (2014–2023)Ralph A. DeFronzo · Georgetown University2 papers (2013–2013) · 2 papers (2013–2018)Stephen Clement · Georgetown University2 papers (2013–2013) · 2 papers (2013–2014)Abbas E. Kitabchi · Wake Forest University2 papers (2013–2013) · 2 papers (2013–2018) · 2 papers (2013–2014)Dawn C. Schwenke · Georgetown University2 papers (2013–2013)Peter D. Reaven · University of Phoenix2 papers (2013–2013)Frankie B. Stentz · Georgetown University2 papers (2013–2013)Nicolas Musi · Veroscience (United States)2 papers (2013–2013)George A. Bray · Kaiser Permanente Walnut Creek Medical Center2 papers (2013–2013)Thomas A. Buchanan · Keck Hospital of USC2 papers (2013–2013)Devjit Tripathy · Georgetown University2 papers (2013–2013)Amalia Gastaldelli · National Health Council2 papers (2013–2013)